EMBRACE - Early detection of Brain Cancer using a novel spectroscopic liquid biopsy enabling timely detection and diagnosis for patient benefit

Dxcover是一家临床阶段诊断公司，致力于为临床提供创新的早期癌症诊断。利用我们的平台技术，我们将提供世界上第一个改变游戏规则的脑癌检测血液测试（Dxcover Brain），该测试无缝地融入当前的标准护理途径。脑癌平均使预期寿命减少20年以上，这一统计数据在很大程度上归因于其晚期发现。诊断途径是非常低效的，因为目前只有约2%的患者被转诊进行成像，实际上患有脑癌。Dxcover的独特技术使用红外光来检测来自肿瘤的信号和来自身体对肿瘤的反应的信号。目前，我们在多项临床研究中对超过3000例患者样本进行了验证，为早期癌症检测提供了简单的工作流程和快速且经济实惠的解决方案。EIC的资助将使Dxcover获得CE-IVDR批准，瞄准欧洲市场，更快地接触患者。

Dxcover is a clinical stage diagnostics company, dedicated to delivering innovative early cancer diagnostics to the clinic. Using our platform technology, we will provide the world’s first game-changing blood test for brain cancer detection (Dxcover Brain) that fits seamlessly into current standard-of-care pathway. Brain cancer reduces life expectancy by over 20 years on average, a statistic that is largely attributed to its late detection. The diagnostic pathway is highly inefficient, as currently only ~2% of patients referred for imaging actually have brain cancer. Dxcover’s unique technology uses infrared light to detect signals from the tumour and signals from the body’s response to the tumour. Currently validated in >3000 patient samples across multiple clinical studies, we provides a simple workflow, and a fast and affordable solution for early cancer detection. EIC funding will allow Dxcover to obtain CE-IVDR approval, target the European market and reach the patient faster.